ERBB2 and breast carcinoma: In fact, as showed in almost all in vitro cell experiments, the antineoplastic activity of MEL alone used at a sub-toxic concentration (IC10) was higher than that of the free drug (FLV-R) and is in accordance with several recent research studies (Sangboonruang et al., 2020; Yu et al., 2020) such as that carried out by Duffy et al. showing the ability of MEL to suppress epidermal growth factor receptors 1 and 2 (EGFR and HER2) activation in the aggressive triple-negative and HER2-enriched breast cancer subtypes (Duffy et al., 2020).